{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:24:49Z","timestamp":1789457089647,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02618-3","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:02:13Z","timestamp":1776038533000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial"],"prefix":"10.1038","volume":"11","author":[{"given":"Junlong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4493-115X","authenticated-orcid":false,"given":"Xinghai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranlu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongquan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benkang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxian","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Perabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"2618_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"2618_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James, N. D. et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 403, 1683\u20131722 (2024).","journal-title":"Lancet"},{"key":"2618_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5534\/wjmh.180040","volume":"37","author":"K Fujita","year":"2019","unstructured":"Fujita, K. & Nonomura, N. Role of androgen receptor in prostate cancer: a review. World J. Mens. Health 37, 288\u2013295 (2019).","journal-title":"World J. Mens. Health"},{"key":"2618_CR4","doi-asserted-by":"publisher","first-page":"122270","DOI":"10.1016\/j.lfs.2023.122270","volume":"336","author":"S Khan","year":"2024","unstructured":"Khan, S., Baligar, P., Tandon, C., Nayyar, J. & Tandon, S. Molecular heterogeneity in prostate cancer and the role of targeted therapy. Life Sci 336, 122270 (2024).","journal-title":"Life Sci"},{"key":"2618_CR5","doi-asserted-by":"publisher","first-page":"732599","DOI":"10.3389\/fonc.2021.732599","volume":"11","author":"Z Wei","year":"2021","unstructured":"Wei, Z., Chen, C., Li, B., Li, Y. & Gu, H. Efficacy and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Front. Oncol. 11, 732599 (2021).","journal-title":"Front. Oncol."},{"key":"2618_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.eururo.2014.07.028","volume":"68","author":"K Brasso","year":"2015","unstructured":"Brasso, K. et al. Enzalutamide antitumor activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: A multicenter analysis. Eur. Urol. 68, 317\u2013324 (2015).","journal-title":"Eur. Urol."},{"key":"2618_CR7","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/ijc.33706","volume":"149","author":"X Li","year":"2021","unstructured":"Li, X. et al. Phase I clinical trial of HC-1119: a deuterated form of enzalutamide. Int. J. Cancer 149, 1473\u20131482 (2021).","journal-title":"Int. J. Cancer"},{"key":"2618_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/jlcr.3516","volume":"60","author":"X Pang","year":"2017","unstructured":"Pang, X., Peng, L. & Chen, Y. Effect of N-methyl deuteration on pharmacokinetics and pharmacodynamics of enzalutamide. J. Labeled Comp. Radiopharm 60, 401\u2013409 (2017).","journal-title":"J. Labeled Comp. Radiopharm"},{"key":"2618_CR9","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.2147\/DDDT.S111352","volume":"10","author":"J Jiang","year":"2016","unstructured":"Jiang, J. et al. Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide. Drug Des. Devel. Ther. 10, 2181\u20132191 (2016).","journal-title":"Drug Des. Devel. Ther."},{"key":"2618_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/ajco.13142","volume":"15","author":"D He","year":"2019","unstructured":"He, D. et al. A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China. Asia Pac. J. Clin. Oncol. 15, 144\u2013150 (2019).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"2618_CR11","first-page":"646","volume":"56","author":"Chinese Anticancer Association Genitourinary Oncology Committee","year":"2018","unstructured":"Chinese Anticancer Association Genitourinary Oncology Committee Chinese experts consensus on the treatment of metastatic prostate cancer 2018 edition. Chin. J. Surg. 56, 646\u2013652 (2018).","journal-title":"Chin. J. Surg."},{"key":"2618_CR12","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","volume":"20","author":"DJ Khalaf","year":"2019","unstructured":"Khalaf, D. J. et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicenter, randomized, open-label, phase 2, crossover trial. Lancet Oncol 20, 1730\u20131739 (2019).","journal-title":"Lancet Oncol"},{"key":"2618_CR13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376, 1147\u20131154 (2010).","journal-title":"Lancet"},{"key":"2618_CR14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091\u20131103 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2618_CR15","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187\u20131197 (2012).","journal-title":"N. Engl. J. Med."},{"key":"2618_CR16","unstructured":"FDA. Highlights of prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203415s014lbl.pdf (2012)."},{"key":"2618_CR17","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.20.02759","volume":"39","author":"SR Denmeade","year":"2021","unstructured":"Denmeade, S. R. et al. TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer. J. Clin. Oncol. 39, 1371\u20131382 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2618_CR18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris, M. J. et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomized, controlled trial. Lancet 404, 1227\u20131239 (2024).","journal-title":"Lancet"},{"key":"2618_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.euo.2024.08.006","volume":"8","author":"M Ruiz-Vico","year":"2025","unstructured":"Ruiz-Vico, M. et al. Liquid biopsy in progressing prostate cancer patients starting docetaxel with or without enzalutamide: a biomarker study of the PRESIDE phase 3b trial. Eur. Urol. Oncol. 8, 135\u2013144 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"2618_CR20","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher, H. I. et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J. Clin. Oncol. 34, 1402\u20131418 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2618_CR21","unstructured":"ICH. ICH Guidelines, https:\/\/www.ich.org\/page\/ich-guidelines (2025)."},{"key":"2618_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur. J. Cancer 62, 132\u2013137 (2016).","journal-title":"Eur. J. Cancer"},{"key":"2618_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.2010.34.2808","volume":"30","author":"M Rimawi","year":"2012","unstructured":"Rimawi, M. & Hilsenbeck, S. G. Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias?. J. Clin. Oncol. 30, 453\u2013458 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2618_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07412-y","volume":"24","author":"V Prasad","year":"2023","unstructured":"Prasad, V., Kim, M. S. & Haslam, A. Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use. Trials 24, 373 (2023).","journal-title":"Trials"},{"key":"2618_CR25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40273-014-0145-y","volume":"32","author":"KJ Ishak","year":"2014","unstructured":"Ishak, K. J. et al. Methods for adjusting for bias due to crossover in oncology trials. Pharmacoeconomics 32, 533\u2013546 (2014).","journal-title":"Pharmacoeconomics"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02618-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02618-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02618-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:02:15Z","timestamp":1776038535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02618-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2618"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02618-3","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}